OBJECTIVE: Hyperandrogenemia, insulin resistance, and dyslipidemia demonstrate familial aggregation in the female first-degree relatives of women with polycystic ovary syndrome (PCOS), suggesting that these defects are heritable. Hyperandrogenemia also appears to be the male reproductive phenotype. We performed this study to test the hypothesis that brothers of women with PCOS have metabolic defects similar to those of their proband sisters. RESEARCH DESIGN AND METHODS: This was a prospective case-control study performed at four academic medical centers in the U.S. Fasting blood was obtained from 196 non-Hispanic white brothers of women with PCOS and 169 control men of age, BMI, and ethnicity comparable to those of brothers. A separate analysis was performed by study site to assess potential regional variations in metabolic parameters. RESULTS: Overall, brothers of women with PCOS had significantly higher total (P = 0.001) and LDL cholesterol (P = 0.01) as well as triglyceride levels (P = 0.01) compared with control men, although there were regional variations in these differences. There were significant positive correlations between brothers and their sisters with PCOS for total (rho = 0.2, P = 0.009) and LDL cholesterol (rho = 0.3, P = 0.001) and triglyceride (rho = 0.2, P = 0.05) levels. Brothers also had significantly higher fasting insulin levels and homeostatic index of insulin resistance (P = 0.02 for both comparisons) compared with control men. CONCLUSIONS: Brothers of women with PCOS have dyslipidemia as well as evidence for insulin resistance similar to that of their proband sisters with PCOS. These findings are consistent with the hypothesis that some metabolic abnormalities in PCOS are heritable and are not sex specific.
OBJECTIVE:Hyperandrogenemia, insulin resistance, and dyslipidemia demonstrate familial aggregation in the female first-degree relatives of women with polycystic ovary syndrome (PCOS), suggesting that these defects are heritable. Hyperandrogenemia also appears to be the male reproductive phenotype. We performed this study to test the hypothesis that brothers of women with PCOS have metabolic defects similar to those of their proband sisters. RESEARCH DESIGN AND METHODS: This was a prospective case-control study performed at four academic medical centers in the U.S. Fasting blood was obtained from 196 non-Hispanic white brothers of women with PCOS and 169 control men of age, BMI, and ethnicity comparable to those of brothers. A separate analysis was performed by study site to assess potential regional variations in metabolic parameters. RESULTS: Overall, brothers of women with PCOS had significantly higher total (P = 0.001) and LDL cholesterol (P = 0.01) as well as triglyceride levels (P = 0.01) compared with control men, although there were regional variations in these differences. There were significant positive correlations between brothers and their sisters with PCOS for total (rho = 0.2, P = 0.009) and LDL cholesterol (rho = 0.3, P = 0.001) and triglyceride (rho = 0.2, P = 0.05) levels. Brothers also had significantly higher fasting insulin levels and homeostatic index of insulin resistance (P = 0.02 for both comparisons) compared with control men. CONCLUSIONS: Brothers of women with PCOS have dyslipidemia as well as evidence for insulin resistance similar to that of their proband sisters with PCOS. These findings are consistent with the hypothesis that some metabolic abnormalities in PCOS are heritable and are not sex specific.
Authors: Barbara A Gower; Wesley M Granger; Frank Franklin; Richard M Shewchuk; Michael I Goran Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: Richard S Legro; Allen R Kunselman; Lawrence Demers; Steve C Wang; Rhonda Bentley-Lewis; Andrea Dunaif Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield Journal: Arch Intern Med Date: 2003-02-24
Authors: Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott Journal: Endocrine Date: 2012-06-04 Impact factor: 3.633
Authors: D M Liu; L C Torchen; Y Sung; R Paparodis; R S Legro; S K Grebe; R J Singh; R L Taylor; A Dunaif Journal: Hum Reprod Date: 2014-10-21 Impact factor: 6.918
Authors: Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro Journal: Endocr Rev Date: 2015-10 Impact factor: 19.871
Authors: Kristen Kobaly; Priyathama Vellanki; Ryan K Sisk; Loren Armstrong; Ji Young Lee; Jungwha Lee; M Geoffrey Hayes; Margrit Urbanek; Richard S Legro; Andrea Dunaif Journal: J Clin Endocrinol Metab Date: 2014-05-30 Impact factor: 5.958
Authors: Mary E Rausch; Richard S Legro; Huiman X Barnhart; William D Schlaff; Bruce R Carr; Michael P Diamond; Sandra A Carson; Michael P Steinkampf; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Linda C Giudice; Phyllis C Leppert; Evan R Myers; Christos Coutifaris Journal: J Clin Endocrinol Metab Date: 2009-06-09 Impact factor: 5.958